Astrazeneca Plc News Today

Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the next five years. The worlds largest vaccine maker, based in Pune, currently has the capacity to produce 3 billion doses annually but only sells about half of that. CEO Adar Poonawalla is optimistic about the increasing uptake of vaccines globally as countries boost their healthcare budgets.

/PRNewswire/ -- The global over-the-counter (OTC) analgesics market size is estimated to grow by USD 7.20 billion from 2024-2028, according to Technavio. The...

/PRNewswire/ -- The global protein therapeutics market size is estimated to grow by USD 172.8 billion from 2024-2028, according to Technavio. The market is...

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit compleme...

Dublin, May 28, 2024 (GLOBE NEWSWIRE) -- The

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

/PRNewswire/ -- The global lung cancer therapeutics market size is estimated to grow by USD 10.52 billion from 2024-2028, according to Technavio. The market is...

/PRNewswire/ -- Allied Market Research has recently published a report, titled, "Degenerative Disc Disease Treatment Market Size, Share, Competitive Landscape...

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.